An estimated 200 million people have been infected with hepatitis C virus (HCV) with a majority unable to clear the virus. Chronic HCV infection can lead to cirrhosis, hepatocellular carcinoma, and end-stage liver disease. It is generally believed that disease results at least in part from immune mediated inflammation. Since HCV’s discovery in 1989 significant progress has been made in establishing experimental systems and unraveling the details of the virus lifecycle. Examples include viral enzyme assays, infectious molecular clones, RNA replicons and finally robust cell culture systems recapitulating the entire virus lifecycle. Definition of the human factors required for HCV entry and blunting innate immune response pathways has led to the development of a mouse model that supports HCV entry, replication and virus production. Together these tools have increased our understanding of the HCV lifecycle and revealed multiple steps for therapeutic intervention. Although painstakingly slow at times, we are finally at the cusp of a revolution in HCV treatment with the advent of well tolerated, all oral, pan genotype regimens that can achieve virologic cure rates in excess of 95%. Challenges remain but we now have the tools in hand to write the final chapter of a remarkable biomedical success story.